Literature DB >> 12791936

Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activity.

Tamara R Anderegg, Douglas J Biedenbach, Ronald N Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12791936      PMCID： PMC156485          DOI： 10.1128/JCM.41.6.2795-2796.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


× No keyword cloud information.
  4 in total

Review 1.  Gram-positive resistance: challenge for the development of new antibiotics.

Authors:  F Baquero
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

2.  Staphylococcus aureus resistant to vancomycin--United States, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-05       Impact factor: 17.586

3.  In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic.

Authors:  G Candiani; M Abbondi; M Borgonovi; G Romanò; F Parenti
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

4.  In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent.

Authors:  R N Jones; D J Biedenbach; D M Johnson; M A Pfaller
Journal:  J Chemother       Date:  2001-06       Impact factor: 1.714
  4 in total
  12 in total

1.  Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent.

Authors:  Robert P Rennie; Laura Koeth; Ronald N Jones; Thomas R Fritsche; Cindy C Knapp; Scott B Killian; Beth P Goldstein
Journal:  J Clin Microbiol       Date:  2007-08-01       Impact factor: 5.948

2.  Meningitis due to vancomycin-resistant Enterococcus faecium successfully treated with combined intravenous and intraventricular chloramphenicol.

Authors:  Pablo Gustavo Scapellato; Cecilia Ormazabal; José Luis Scapellato; Edgardo Gabriel Bottaro
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

3.  Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms.

Authors:  Thomas R Fritsche; Robert P Rennie; Beth P Goldstein; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

4.  Bactericidal activity and resistance development profiling of dalbavancin.

Authors:  Beth P Goldstein; Deborah C Draghi; Daniel J Sheehan; Patricia Hogan; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

5.  Antipneumococcal activity of dalbavancin compared to other agents.

Authors:  Gengrong Lin; Kathy Smith; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.

Authors:  David J Farrell; Rodrigo E Mendes; Paul R Rhomberg; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

7.  Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.

Authors:  Douglas J Biedenbach; James E Ross; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

8.  Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.

Authors:  Gengrong Lin; Kim Credito; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

9.  A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.

Authors:  Laura M Koeth; Jeanna M DiFranco-Fisher; Sandra McCurdy
Journal:  J Vis Exp       Date:  2015-09-09       Impact factor: 1.355

10.  Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Authors:  Francis F Arhin; Ingrid Sarmiento; Adam Belley; Geoffrey A McKay; Deborah C Draghi; Parveen Grover; Daniel F Sahm; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.